GLP1R and obesity due to melanocortin 4 receptor deficiency: For patients presenting with the triad of OSA, obesity, and diabetes (or those at risk for diabetes), GLP-1 receptor agonists have proven benefits and should be considered as adjunctive therapy to the conventional one, mainly in patients with obesity or T2DM.